NIDILRR Will Make 11 SBIR Phase I Awards at $100,000 Each. Universities Cannot Compete for Them.

Assistive- and rehab-technology founders chasing SBIR money outside the Pentagon and NIH have a new door: the Administration for Community Living posted forecast HHS-2027-ACL-NIDILRR-BISA-0308 to grants.gov on September 25, 2026 — 11 Phase I awards at a $100,000 ceiling, applications due December 16.

That is the entire program. Eleven grants, $1,100,000 total, six months of performance each. Measured against the $4 billion-plus that flows through the federal SBIR program annually, it is a rounding error. Measured against the number of small businesses that build wheelchair components, prosthetic controllers, screen readers, communication boards, and job-coaching software — and have nowhere obvious to take them inside the federal R&D system — it is one of the few doors that exists at all.

A $1.1 Million Set-Aside Hiding in a Forecast Notice

The grants.gov listing for opportunity 363966 is a forecast, not a live solicitation. That distinction matters operationally and almost nobody acts on it correctly.

Here is what the forecast record actually commits to. The National Institute on Disability, Independent Living, and Rehabilitation Research — NIDILRR, housed inside ACL — plans 11 Phase I grants under Assistance Listing 93.433. The award ceiling is $100,000 and the floor is $95,000, which means there is effectively one price: you are writing a $100,000 budget. Estimated total program funding is $1,100,000. There is no cost-sharing or matching requirement. The project period is six months, with a single corresponding six-month budget period.

The dates are the part founders should transcribe into a calendar today. The full notice of funding opportunity — the synopsis, in grants.gov terminology — is estimated to post October 16, 2026. Applications are estimated due December 16, 2026. Awards and project start are both estimated for June 1, 2027, and the forecast archives September 30, 2027. The program contact listed is Brian Bard at ACL (brian.bard@acl.hhs.gov, 202-795-7298).

Eligibility language is narrow and worth reading literally: each applicant "must qualify at the time of the award as a small business concern as defined by the Small Business Administration," and "foreign entities are not eligible to compete for, or receive, awards made under this announcement." Applicant type on the record is a single entry — small businesses. No universities, no nonprofits, no hospital systems as prime. If you have been losing NIDILRR competitions to academic medical centers, this is the one mechanism where they cannot enter.

Why the $100,000 Ceiling Is the Strategy, Not the Flaw

SBA's inflation-adjusted Phase I guideline for 2026 sits above $314,000. NIH routinely awards Phase I near that line. NASA raised its Phase I ceiling 50 percent to $225,000 when it moved to a rolling Broad Agency Announcement model — a shift we covered in detail in NASA Just Overhauled How It Funds Small Business Innovation. Against that field, ACL's $100,000 over six months looks like a consolation prize.

It is better understood as a deliberately cheap feasibility gate. Six months and $100,000 buys roughly one engineer, one clinical or usability consultant, and a small participant sample. It does not buy a prototype iteration cycle, a regulatory pathway analysis, and a pilot trial. NIDILRR is not pretending otherwise: the forecast describes Phase I as work "to determine the scientific or technical merit and feasibility of concepts, topics, or ideas." Full stop.

The practical consequence is that a competitive Phase I application here has a much smaller technical scope than a competitive NIH R43. Founders who port an NIH-sized aim structure into a $100,000 six-month budget produce applications that reviewers read as unfundable on their face. The correct move is the opposite of ambition inflation: one testable feasibility question, one participant sample, one measurable go/no-go criterion, and an explicit sentence about what Phase II would do with the answer.

The Real Competition Is for Four Slots, Not Eleven

The Phase I notice does not stand alone. ACL forecast its companion mechanism the same day: HHS-2027-ACL-NIDILRR-BISB-0309, SBIR Phase II, with 4 planned awards, $1,150,000 in estimated total funding, an award ceiling of $287,500, and a floor of $280,000. Its synopsis is estimated to post December 1, 2026, with applications due February 1, 2027 and awards also starting June 1, 2027.

Sit with those two numbers. Eleven Phase I awards feeding four Phase II slots. NIDILRR spends almost exactly as much on four Phase II grants ($1.15 million) as on eleven Phase I grants ($1.1 million). That is a structural conversion rate in the mid-thirties — better than most founders assume, and far better than the Phase I-to-Phase II odds at agencies where Phase I cohorts run into the hundreds.

It also tells you where the value is. A $100,000 Phase I award is not the prize; it is the ticket to compete for $287,500 per year over two years, which is where a genuine development program becomes fundable. The implication for how you write Phase I is direct: the six-month scope should be engineered to generate exactly the evidence a Phase II panel will demand. Feasibility data that is interesting but not Phase II-shaped wastes the slot.

Note also the timing overlap. Phase II applications are due February 1, 2027, while FY2027 Phase I awards do not start until June 1, 2027. The Phase II competition you would enter in early 2027 is fed by earlier Phase I cohorts, not this one. If you win under BISA-0308, your Phase II shot is the FY2028 cycle — roughly a two-and-a-half-year arc from December 2026 application to Phase II start. Plan capital accordingly.

Three Outcome Domains Decide Whether You Are Actually Eligible

Formal eligibility is the SBA small-business test. Substantive eligibility is narrower, and it is where most first-time NIDILRR applicants get screened out.

Every SBIR project NIDILRR funds must address the needs of people with disabilities and advance one of three outcome domains drawn from the institute's Long Range Plan: health and function, community living and participation, or employment. The Phase II forecast states this explicitly; the Phase I description carries the same framing through ACL's program purpose language about improving "the lives of people with disabilities through R/R&D products generated by small businesses."

This is not boilerplate you can satisfy with a sentence. A company with a general-purpose computer-vision product does not become NIDILRR-eligible by adding a paragraph about accessibility. The project has to be organized around a disability outcome, with the target population specified and, in NIDILRR's tradition, evidence that diverse racial and ethnic populations of people with disabilities are represented in the research sample. Universal design principles carry real weight in review.

Past cohorts show what clears the bar. A recent Phase I class funded wearable hand exoskeletons for post-stroke rehabilitation, an exergaming system for hand and arm function in children with cerebral palsy, a smart wheelchair cushion aimed at reducing pressure injuries, a sound-based augmented-reality tool for accessible STEM learning, a smart cranial orthosis with electronic notification, and social-skills technology for employed autistic adults. The pattern is a specific device or protocol, a named population, and a functional outcome — not a platform.

What the Rest of the FY2027 NIDILRR Slate Tells You

ACL forecast its entire FY2027 research portfolio on September 25, 2026, and reading the slate together is more useful than reading the SBIR notice alone.

Two Field Initiated Projects competitions — HHS-2027-ACL-NIDILRR-IFRE-0303 (Research) and HHS-2027-ACL-NIDILRR-IFDV-0304 (Development) — each plan 8 awards with $2,000,000 in estimated funding and a $250,000 ceiling, with synopses estimated October 12, 2026 and applications due December 14, 2026. The Development variant in particular funds work to "create materials, devices, systems, methods, measures, techniques, tools, prototypes, processes, or intervention protocols." Two Rehabilitation Engineering Research Centers are forecast at $975,000 each — one on recreational, sport, and exercise technologies, one on technologies for people who are blind or have low vision — with April 2027 deadlines and 60-month project periods.

For a founder, that is a sequencing map, not a menu. Field Initiated Development and SBIR Phase I close within 48 hours of each other in December 2026, which means you choose rather than hedge. And the RERC awards are the partnership targets: a five-year, $975,000-per-year center on blind and low-vision technology is exactly the kind of institution a hardware startup should be talking to now about validation sites and co-investigators for a 2027 or 2028 submission.

One caution on forecasts. Every date above is an agency estimate on a record created September 25, 2026, not a published deadline. Synopsis posting dates slip, planned award counts get revised downward when appropriations land late, and ACL has been through enough organizational change in the past two years that the FY2027 slate is worth re-verifying in mid-October rather than assumed. Set a reminder for October 16 and check whether BISA-0308 has converted from forecast to posted.

Working the October 16 Window

The eight weeks between an October 16 synopsis and a December 16 deadline is a short runway for a six-month, $100,000 project — but it is short in a way that favors prepared applicants over well-resourced ones. There is no page-count arms race to lose here.

Three things are worth doing before the notice posts. Confirm your SAM.gov registration and UEI are active and will not expire during the window, because that is the single most common reason a small business misses a December deadline. Write the one-sentence feasibility question and the go/no-go criterion now, while you are not under deadline pressure. And email Brian Bard to ask whether the FY2027 notice retains the same three-domain structure and whether the six-month period is firm — program officers answer that kind of specific question, and the answer shapes your scope.

The NIDILRR lane is small, non-DoD, non-NIH, and almost entirely uncovered by the SBIR consulting industry. Eleven awards is not many. But eleven awards in a competition that excludes universities, excludes foreign entities, and requires a disability outcome most generalist applicants cannot credibly claim is a meaningfully better shot than the raw number suggests.

Next step: Search active SBIR Phase I solicitations across HHS and other civilian agencies on Granted — then set a watch on ACL/NIDILRR so you see BISA-0308 the day it converts from forecast to posted.